TECX at a glance
Tectonic Therapeutic, Inc. (TECX, SEC CIK 1681087) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Tectonic Therapeutic, Inc. (TECX) shares worth $76.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by McNamara Peter on September 30, 2026 of 536 shares at $23.04 per share.
- In the last 90 days, TECX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($14K) on Form 4, a net sale of $14K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$14K
- 13F holders
- 22 funds
- $76.0M · −3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales
- Operating expenses $23.5M vs $21.9M YoY, operating loss $23.5M vs $21.9M
- Best program: TX45 R&D $5.7M vs $6.0M, down $0.4M; highest spend: platform $8.4M vs $7.0M
- Cash $234.7M at September 30; nine-month operating cash use $54.8M vs $45.6M
- APEX topline results expected by January 2027; TERRA planned by year-end 2026 amid additional funding needs
Risk Factors
- Newly added regulatory risk: September 2026 FDA Fast Track designation for TX2100 does not assure accelerated review or marketing approval
- Most materially updated market risk: AstraZeneca discontinued AZD3427 in February 2026, while AZD5462 showed Phase 2 efficacy, heightening relaxin-pathway competition
- Compliance risk: December 2025 BIOSECURE Act could restrict work with designated Chinese biotechnology companies, threatening TX45 supply
- Operational risk: WuXi Biologics remains the sole TX45 supplier, exposing clinical timelines to manufacturing disruption
- Financial risk: $234.7 million cash and cash equivalents as of September 30, 2026, expected to fund operations for at least 12 months
AI summary of the TECX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Third-quarter results for the period ended September 30, 2026 announced
- General business update accompanying the quarterly financial release
Item EX-99.1: Item EX-99.1
- Q3 2026 net loss $21.3M, or $1.08 per share, versus $19.0M and $1.02 in Q3 2025
- Cash $234.7M, including approximately $22.3M ATM proceeds, supports runway into Q1 2029 under current assumptions
Item 8.01: Other Events
- Phase 1 TX2100 results favorable for safety, tolerability and pharmacokinetics
- TX2100 targets hereditary hemorrhagic telangiectasia, expanding Tectonic’s clinical pipeline
Item EX-99.1: Item EX-99.1
- Phase 1a TX2100 doses generally safe and tolerated across six cohorts in 48 healthy volunteers
- No deaths, serious adverse events, or severe treatment-emergent adverse events; anti-drug antibody results pending
Item EX-99.1: Item EX-99.1
- Q2 2026 earnings update: net loss $22.3M versus $20.0M, with R&D expense rising to $18.0M
- TX45 APEX Phase 2 enrollment complete: 191 patients, including 137 enriched CpcPH patients; topline results expected early Q1 2027
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026 announced
- General business update accompanies earnings release
AI summaries of TECX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TECX
Don't miss the next TECX filing
- Alerts as it files. A push when TECX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TECX, by share count.
- Ask anything. An AI agent that reads every TECX filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| REICIN ALISE | M | Oct 26, 2026 | 10,000 | $2.38 |
| REICIN ALISE | M | Oct 26, 2026 | 10,000 | - |
| McNamara Peter | Sell | Sep 30, 2026 | 536 | $23.04 |
| McNamara Peter | F | Sep 25, 2026 | 444 | $23.67 |
| Lochner Daniel | F | Sep 25, 2026 | 520 | $23.67 |
| Ruddy Marcella K. | F | Sep 25, 2026 | 525 | $23.67 |
| Schwabish Marc | F | Sep 25, 2026 | 411 | $23.67 |
| REICIN ALISE | F | Sep 25, 2026 | 1,545 | $23.67 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | $10.2M | -$58.0M | -$84.0M |
| Net Income | - | -$58.0M | -$74.2M |
| Balance Sheet | |||
| Total Assets | $101.1M | $152.9M | $261.0M |
| Equity | $94.7M | $140.8M | $251.3M |
| ROE | - | -41.2% | -29.5% |
| Per Share | |||
| EPS | $0.27 | $-6.83 | $-4.05 |
| Cash Flow | |||
| Operating CF | -$63.2M | -$59.1M | -$60.1M |
| CapEx | $8K | $156K | $208K |
Source: XBRL data in Tectonic Therapeutic, Inc. (TECX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TECX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $76.0M |
| Q2 2026 | 25 | $195.7M |
| Q1 2026 | 23 | $167.5M |
| Q4 2025 | 19 | $120.5M |
| Q3 2025 | 17 | $86.0M |
| Q2 2025 | 18 | $99.7M |
| Q1 2025 | 15 | $72.6M |
| Q4 2024 | 12 | $100.7M |
- Raymond James Financial+124.7K (+172%)
- Goldman Sachs Group+110.5K (+149%)
- Citadel Advisors LLC+102.6K (+114%)
- Vanguard Portfolio Management LLC+44.3K (+47%)
- Dimensional Fund Advisors+43.3K (+414%)
- Millennium Management−38.6K (-23%)
- D.E. Shaw & Co−4.0K (-2%)
- Citigroup−2.7K (-49%)
- Wells Fargo & Co−1.9K (-2%)
- BlackRock−1.9K (-0%)
- FMR LLC (Fidelity)−2.83M
- AQR Capital Management−6.6K
- Invesco Ltd−6.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 151 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TECX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TECX SEC filings: frequently asked questions
Are TECX insiders buying or selling?
In the last 90 days, Tectonic Therapeutic, Inc. (TECX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $13,920 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TECX stock?
As of September 30, 2026, the largest Tectonic Therapeutic, Inc. (TECX) holders among the 13F filers tracked by SignalX were BlackRock ($20.0 million), Vanguard Capital Management LLC ($11.9 million), State Street Corp ($5.1 million), Raymond James Financial ($4.6 million), Citadel Advisors LLC ($4.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TECX report in its latest 8-K?
Tectonic Therapeutic, Inc. (TECX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for the period ended September 30, 2026 announced.
What are the latest TECX SEC filings?
Tectonic Therapeutic, Inc. (TECX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 28, 2026.
What is TECX's SEC CIK number?
Tectonic Therapeutic, Inc. (TECX)'s SEC Central Index Key (CIK) is 1681087. EDGAR lists every TECX filing under that number.
Ask anything about TECX
The research agent reads TECX's filings, financials, insider trades and 13F holders, then answers with sources.